Wilmington, Delaware, United States, Transparency Market Research, Inc. , July 19, 2024 (GLOBE NEWSWIRE) -- The global gastroparesis treatment market (위마비 치료 시장) stood at US$ 6.3 billion in 2023, and the global market is projected to reach US$ 10.3 billion in 2034. The gastroparesis treatment market is anticipated to expand at a CAGR of 4.6% between 2024 and 2034.
The global gastroparesis treatment market is experiencing steady growth driven by factors such as increasing prevalence of diabetes, rising awareness and diagnosis rates, and advancements in treatment options. Gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, affects millions worldwide, predominantly individuals with diabetes.
The primary driver of the gastroparesis treatment market is the growing diabetic population. Diabetes is a leading cause of gastroparesis due to nerve damage (neuropathy) affecting the stomach muscles and nerves controlling digestion. As diabetes prevalence rises globally, particularly in developed regions like North America and Europe, the incidence of gastroparesis also increases, thereby boosting demand for effective treatments.
Download Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39305
Treatment approaches for gastroparesis focus on managing symptoms and improving gastric motility. Pharmacological therapies include prokinetic agents such as metoclopramide, domperidone, and erythromycin, which help stimulate stomach contractions and enhance gastric emptying. Antiemetics like ondansetron are used to alleviate nausea and vomiting associated with gastroparesis.
In addition to medications, dietary modifications play a crucial role in managing gastroparesis. Patients are advised to consume smaller, more frequent meals, low in fiber and fat, to ease digestion. Nutritional support through liquid diets or nutritional supplements may be necessary for severe cases where oral intake is compromised.
Emerging treatments include gastric electrical stimulation (GES), where a device implanted in the abdomen helps regulate stomach contractions. This therapy is beneficial for patients who do not respond to medications. Additionally, botulinum toxin injections into the pylorus—a procedure known as pyloric botulinum toxin injection—can also improve gastric emptying in some cases.
The competitive landscape of the gastroparesis treatment market is characterized by ongoing research and development efforts by pharmaceutical companies to introduce novel therapies. Companies are investing in clinical trials to evaluate new drug candidates and exploring innovative approaches to improve patient outcomes.
Top Companies
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG
- Cipla Limited
- Evoke Pharma
- Pfizer Inc.
- Salix Pharmaceuticals, Inc.
- The Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
Gastroparesis Treatment Market: Key Players
- In 2023, Abbott Laboratories continued to innovate in the gastroparesis treatment market with advancements in their diagnostic and monitoring technologies. Abbott's gastric electrical stimulation (GES) systems, such as the Enterra II system, gained traction for managing symptoms of gastroparesis by helping to regulate gastric motility through electrical impulses.
- In 2023, AbbVie Inc. focused on expanding its portfolio in the gastroparesis treatment market by advancing clinical trials for their drug, Velusetrag (TD-5108). Velusetrag, a selective 5-HT4 receptor agonist, aims to improve gastric emptying and alleviate symptoms of gastroparesis.
Key Takeaways of Market Report
- Global gastroparesis treatment market to generate absolute dollar opportunity worth US$ 6.3 billion until 2034.
- Global gastroparesis treatment market is valued at US$ 10.3 billion in 2023.
- North America is forecasted to hold the largest share in 2023.
Gastroparesis Treatment Market: Growth Drivers
- Diabetic gastroparesis is a complication resulting from poorly controlled diabetes, causing dysfunction in the autonomic nervous system, interstitial cells of Cajal (ICC), and neurons. Damage to the vagus nerve due to prolonged hyperglycemia leads to delayed stomach emptying, manifesting in symptoms like nausea, early satiety, weight loss, and vomiting.
- CinDome Pharma has embarked on advancing Deudomperidone (CIN-102) through Phase II trials for diabetic gastroparesis treatment. Securing US$ 40 million in Series B financing highlights significant investment in developing this potential therapy.
- This funding aims to accelerate clinical development, positioning Deudomperidone as a promising candidate in the quest to alleviate symptoms and improve the quality of life for individuals suffering from chronic gastroparesis.
Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39305
Gastroparesis Treatment Market: Regional Landscape
- North America, particularly the U.S., dominated the gastroparesis treatment market in 2023, a trend expected to persist due to several factors. The region boasts a significant population at risk of developing diabetes, with CDC data indicating 96 million adults living with prediabetes in 2022, representing 38% of the adult population.
- Additionally, favorable reimbursement policies in the United States incentivize healthcare providers to diagnose and treat gastroparesis promptly. This supportive healthcare environment encourages investment in innovative therapies and ensures access to comprehensive care, further solidifying North America's position as a leader in the gastroparesis treatment market.
Gastroparesis Treatment Market: Segmentation
Drug Class
- Prokinetic Agents
- Antiemetic Drugs
- Proton Pump Inhibitors
- Others (Botulinum Toxin Injections, etc.)
Disease Indication
- Diabetes Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
Type
- Over-the-counter Drugs
- Prescription Drugs
Route of Administration
- Oral
- Injectable
- Nasal
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=39305<ype=S
More Trending Report by Transparency Market Research:
- Healthcare Automation Market (헬스케어 자동화 시장) – The Global Healthcare Automation Market Size Worth USD 88.9 Bn in 2028 Growing at a CAGR of 8.4%, TMR Study
- Durable Medical Equipment (DME) Market (내구성 의료 장비 시장) – The Global Durable Medical Equipment Market to Reach US$ 261 Bn by 2027, TMR Study
- Lucid Dreaming Devices Market (자각몽 장치 시장) – The Global Lucid Dreaming Devices Market is expected reach US$ 196.8 Million by the end of 2034
- Low Endotoxin Gelatin Market (저내독소 젤라틴 시장) - The Global Low Endotoxin Gelatin Market is expected to grow at a CAGR of 6.4% from 2024 to 2034.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
